Ancestry and pharmacogenetics of antileukemic drug toxicity
Top Cited Papers
Open Access
- 30 January 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (10), 4151-4157
- https://doi.org/10.1182/blood-2006-10-054528
Abstract
Treatment-related toxicity in acute lymphoblastic leukemia (ALL) can not only be life threatening but may also affect relapse risk. In 240 patients, we determined whether toxicities were related to 16 polymorphisms in genes linked to the pharmacodynamics of ALL chemotherapy, adjusting for age, race (self-reported or via ancestry-informative markers), sex, and disease risk group (lower- vs higher-risk therapy). Toxicities (gastrointestinal, infectious, hepatic, and neurologic) were assessed in each treatment phase. During the induction phase, when drugs subject to the steroid/cytochrome P4503A pathway predominated, genotypes in that pathway were important: vitamin D receptor (odds ratio [OR], 6.85 [95% confidence interval [CI], 1.73-27.0]) and cytochrome P4503A5 (OR, 4.61 [95% CI, 1.11-19.2]) polymorphisms were related to gastrointestinal toxicity and infection, respectively. During the consolidation phase, when antifolates predominated, the reduced folate carrier polymorphism predicted gastrointestinal toxicity (OR, 10.4 [95% CI, 1.35-80.4]) as it also did during continuation (OR, 2.01 [95% CI, 1.06-4.11]). In all 3 treatment phases, a glucuronosyltransferase polymorphism predicted hyperbilirubinemia (P = .017, P < .001, and P < .001) and methotrexate clearance (P = .028), which was also independently associated with hyperbilirubinemia (P = .026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy.This publication has 43 references indexed in Scilit:
- Population stratification confounds genetic association studies among LatinosHuman Genetics, 2005
- Pharmacogenetics of outcome in children with acute lymphoblastic leukemiaBlood, 2005
- Down syndrome and leukemia: New insights into the epidemiology, pathogenesis, and treatmentPediatric Blood & Cancer, 2004
- Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and CyclophosphamideJournal of Clinical Oncology, 2004
- Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemiaBlood, 2004
- Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With LeukemiaJournal of Clinical Oncology, 2003
- Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapyLeukemia, 2002
- Long-term results of large prospective trials in childhood acute lymphoblastic leukemiaLeukemia, 2000
- Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosisMedical and Pediatric Oncology, 1994
- Potential Long-Term Toxic Effects in Children Treated for Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 1989